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Grand Rounds in
Environmental Medicine:
Information on MCS Needed
In the “Preface” to Grand Rounds in
Environmental Medicine: Cases from an
Emerging Discipline, Howard Hu (2003)
stated that
Part of the value of Grand Rounds stems from
the appreciation that in real life, patients rarely
present with cut-and-dry cases of illnesses as they
are described in medical school. Real people have
unique combinations of preexisting health condi-
tions, symptoms, and complaints.
No truer words have been spoken about a
chemically injured patient—but more
words could be added. Alas, mainstream
doctors are not trained adequately to diag-
nose symptoms and adverse health events
from pesticide poisoning, not even when
the patient describes actual exposures to the
doctor. Try to imagine what it is like for a
patient suffering from perfume poisoning. I
certainly hope that Grand Rounds in
Environmental Medicine will do much to
change that.
I was pleased to see the list of environ-
mental exposures that affect human health—
both those that are more common, such as
lead, mercury, asbestos, organophosphate
pesticides, and polychlorinated biphenyls,
and others that are more unusual, such as
manganese, bromine, and carbon disulfide
(Hu 2003). As Hu (2003) also noted, other
factors are beginning to be accepted as envi-
ronmental health hazards, such as cockroach
allergen and violence.
Hu (2003) continues:
Some [Grand Rounds cases] pertain to illnesses
arising from occupations that entail combina-
tions of exposures that may have acted synergisti-
cally. Some arise out of new research on illnesses
and exposures that had not previously been
linked together, such as infant pulmonary hem-
orrhage/Stachybotrys mold and possible estuary-
associated syndrome. Others explore illnesses
that are still of uncertain etiology and biology,
such as multiple chemical sensitivities.
I would be even more pleased if modern
flavors and fragrances appeared in the list.
I am often displeased to see articles in
mainstream newspapers in which doctors
advise patients with asthma to rid their
homes of the “usual suspects”—cats,
cockroaches, and dust and dust mites,
sometimes including mouse feces and mold
for good measure—without mentioning
the potential harm that fragrance chemicals
can cause for people with asthma or other
diseases exacerbated by fragrance products.
Fragrances are not benign. Each scent is
composed of untold combinations of highly
volatile petrochemical derivatives. How
many of these chemicals are in the air,
being breathed and absorbed by user and
nonuser alike? People have good reasons to
avoid using scented products; for example,
an individual may have adverse reactions to
these products, or a pregnant woman may
be concerned about the welfare of her fetus.
Illnesses that may be affected by petrochem-
ically derived flavors and fragrances include
asthma and other respiratory diseases,
migraines and other headaches, neurologic
events, and even cancer.
Unfortunately, people who do not use
scented products become users nonetheless—
from sharing space with people who use
these products. These chemicals cross not
only the blood–brain barrier but also the
blood–placental barrier. They go directly
through the skin to target organs and are
stored in adipose tissue. Whether these
toxic chemical mixtures are used as flavors
or fragrances, they play a major role in the
adverse health events experienced by mil-
lions of men, women, and children, as well
as developing fetuses. Too often, main-
stream doctors do not consider that modern
pharmaceuticals may be petrochemically
derived and could contain petrochemically
derived flavors and fragrances. No wonder
there are skyrocketing rates of asthma and
cancers, as well as high rates of iatrogenic
diseases and deaths.
The public needs to learn of this infor-
mation through sources such as EHP.
Although it is possible to dig deeply enough
to find some information on government
agency websites, the general public cannot
readily and easily access the information
from the Food and Drug Administration,
the U.S. Environmental Protection Agency,
the Consumer Products Safety Commission,
the Agency for Toxic Substances and Disease
Registry, or the Centers for Disease Control
and Prevention. These agencies have not
done all they could to protect public health
and well-being regarding adverse health
events associated with synthesized flavors and
fragrances.
As EHP builds a “compendium of Grand
Rounds in Environmental Medicine,” I
fervently hope that information will be
included about adverse health effects
caused, triggered, or exacerbated by mod-
ern flavors and fragrances, particularly
those of the last 30 years. The tens to hun-
dreds of chemicals used to build each scent
can cause the varieties of diseases and ill-
nesses associated with multiple chemical
sensitivity (MCS).
It is past time for public agencies,
mainstream medical doctors, and everyone
touched in any way by this life-threatening
and life-changing malady to learn more
about the effects of petrochemically derived
flavors and fragrances. We all are stake-
holders when it comes to breathing.
I appreciate EHP for providing the
forum for presenting and discussing
important topics such as this one. Additional
information on MCS is available on the web
(Environmental Health Network 2004;
Fragranced Products Information Network
2004; Health Care Without Harm 2004;
Manura 1998). 
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The Simple Truth about
Multiple Chemical Sensitivity
Renee Twombly’s news article “The Simple
Truth about MCS” (Twombly 2003)
ignores the plausible physiologic mechanism
(described in the same issue of EHP) that
answers each of the major questions about
multiple chemical sensitivity (MCS) (Pall
2003). Given the many puzzling features of
MCS and the previous claims that there can-
not be a plausible physiologic mechanism to
explain it, the finding of a physiologic mech-
anism (Pall 2002, 2003; Pall and Satterlee
2001) is a landmark in our understanding of
this illness.
This mechanism provides answers to
each of the most important and previously
intractible questions about MCS (Pall 2003),
such as:
• How can the reported exquisite (approxi-
mately 1,000-fold) sensitivity to chemicals
be produced?
• How are the two main classes of chemi-
cals—acetylcholinesterase inhibitors
(organophosphates and carbamates) and
hydrophobic organic chemicals—involved?
• How can previous chemical exposure
induce such sensitivity?
• Why is MCS chronic?
• How are the characteristic symptoms of
MCS generated?
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chronic fatigue syndrome and fibromyalgia?
• How might neurogenic inflammation be
generated as part of the MCS mechanism?
• How can lowering of several steps in por-
phyrin synthesis occur as a consequence of
the MCS mechanism? (Classical porphyria
is caused by lowering a single step in the
pathway, whereas in MCS, several steps in
the pathway are low.) 
We look to articles such as Twombly’s to
connect the most important dots and pro-
duce for the reader the essence of the resul-
tant pattern. I hope that Twombly’s failure
to do so for MCS will be a temporary lapse.
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Multiple Chemical Sensitivity:
Response to Pall
Renée Twombly’s news article (Twombly
2003) was not intended to be a comprehen-
sive discussion of multiple chemical sensi-
tivity. Rather, as per the standing format of
the Science Selections portion of EHP,
Twombly was assigned to summarize the
findings of a particular research article in
the same issue (Gibson 2003). It is beyond
the scope of Science Selections articles to
“connect the most important dots” of what-
ever research topic they summarize, and
Twombly’s failure to do so in her article in
no way reflects upon her. 
Kimberly Thigpen Tart
News Editor, EHP
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Accuracy of Declared Conflicts
of Interest
Growing evidence shows that the findings
and conclusions of researchers with financial
conflicts of interest are significantly more
likely to favor the interests of their for-profit
supporters (Bekelman et al. 2003; Swaen and
Meijers 1988), as does evidence of the take-
over of the institutions of science by for-
profit corporations (Blumenthal et al. 1996;
Willman 2003). However, many authors
remain reluctant to declare the financial ben-
efits they receive (Krimsky and Rothenberg
2001). In elucidating its new conflict of
interest policy, the British Medical Journal
theorized:
We have two hypotheses to explain this. Firstly,
authors think that an admission of a conflict of
interest implies wickedness. We don’t think so.
Secondly, authors are confident that they have
not been influenced by a conflict of interest and
so don’t tell us they have one. Our response is
that bias works in subtle ways and that none of us
is blessed with knowledge of our own motiva-
tions and mental mechanisms. (Smith 1998)
EHP too has strengthened its conflict of
interest policy—to now require authors to
provide a public declaration of competing
interests that could constitute a real, poten-
tial, or apparent financial conflict, and require
they certify their freedom from competing
interests to conduct all aspects of research
(Environmental Health Perspectives 2003).
Unfortunately, author reluctance is evi-
dent. For example, Starr (2003) (of TBS
Associates) recently published a worthy
commentary in EHP in which he analyzed
the controversial and high-financial-stakes
question of the cancer potency of dioxins;
yet he states,
Partial support for this work was provided by the
Chlorine Chemistry Council [CCC]. The author
declares he has no conflict of interest.
In the same issue, Gibson et al. (2003)
reported on their investigation of the efficacy
of therapies for multiple chemical sensitivity
(MCS), as perceived by those taking them.
They state,
This research was supported in part by a grant
from the Chemical Injury Information Network
[CIIN] and a James Madison University Faculty 
Summer Research grant. The authors declare
they have no conflict of interest.
EHP’s long-standing transparency of
author affiliation and funding allows readers
to judge both claims. The corporations that
make up the CCC derive a huge financial
benefit in seeing dioxins and other chlori-
nated chemicals declared safe to the bios-
phere. However, the CIIN, an influential
support group for those with MCS, gains a
small financial benefit from seeing MCS
declared a prevalent hazard, even if the bene-
fit is large relative to the CIIN’s small size.
Readers can factor in the CCC’s dedication
to the narrow interests of for-profit corpora-
tions (almost entirely financial gain) and the
CIIN’s bias toward the very public interest of
health. University and government funders
such as the National Institutes of Health also
represent the broad public interest and are
biased toward health issues.
Journal editors should require declara-
tions (including for correspondence) to be
more truthful. Editors should also declare
their financial conflicts.
What about refusals to declare a financial
conflict when the funding source does not
indicate its presence? Journals should regu-
larly publish a reminder about the impor-
tance of declaring all conflicts of interest, and
they should solicit readers for notification of
undisclosed conflicts and publish any that
are received and verified. 
Author bias is inevitable, but it con-
tributes to scientific discourse—the only
way for humanity to gain knowledge (e.g.,
when a journal publishes, without a conflict
of interest declaration, the proceedings of
symposia that include industry-affiliated
authors). Full transparency is critical to the
advancement of knowledge. 
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cial interest because he received payment from a
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for the Earth) and a trial attorney, both of
whom could profit from the service he provided.
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Conflicts of Interest: Gibson’s
Response
I applaud Tweedale’s effort to ferret out and
expose true conflicts of interest in regard to
health research. However, he is barking up
the wrong tree when he suggests that conflict
of interest was present in my study of per-
ceived treatment efficacy for therapies for
multiple chemical sensitivity (MCS) (Gibson
et al. 2003). Although I admit to having a
strong interest in and caring deeply about
issues relating to my topic of research, I do
not think that this distinguishes me from any
other researcher. 
My funding was from the Chemical
Injury Information Network (CIIN), a
nonprofit organization that works to pro-
vide education and advocacy regarding
MCS. Neither the CIIN nor I have any
vested financial interest whatsoever in any
of the treatments researched. My purpose
for the study was to examine resource allo-
cation for and efficacy of treatments for a
currently delegitimized condition. The
CIIN has an interest in gathering and pro-
viding information to those with MCS
about this issue, but the organization nei-
ther advocates nor benefits from the use or
sale of any particular treatment. Tweedale’s
suggestion that the CIIN may gain finan-
cially from “seeing MCS declared a preva-
lent hazard” seems inappropriate, given
the study’s focus on treatment and not 
prevalence. 
Finally, I clearly disagree with Tweedale’s
suggestion that even funding from the
National Institutes of Health (NIH) is sus-
pect because the NIH has an interest in
health. Nonprofit organizations have been
funding health research for decades and, in
my mind, having an “interest in health” is in
no way synonymous with a financial vested
interest. 
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Editors’ note: Because the phrase “conflict of
interests” can be interpreted so broadly that
almost everyone could be considered to have a
conflict, we modified our policy for declaring
conflicts of interest in December 2003 (Environ
Health Perspect 111:A900–905). EHP now
requires authors to declare “competing financial
interests.” The new policy is available on the web
in our updated Instructions to Authors (http://
ehp.niehs.nih.gov/docs/admin/edpolicy.html);
the new downloadable form is also available
(http://ehp.niehs.nih.gov/cfi.pdf). 
Because EHP is not in the position to confirm
the accuracy of disclosure statements made by our
authors, we hold authors responsible for providing
accurate information. EHP authors can expect
scrutiny of their statements by our readers and by
the authors’ own employers. We welcome letters to
the editor that address alleged inaccuracies of
declarations of competing financial interests.
Six Modern Plagues
In his generally positive review of my book,
Six Modern Plagues and How We Are Causing
Them (Walters 2003), Donald S. Burke
(2004) neglected to mention that Six Modern
Plagues goes out of its way to differentiate
between fact and theory. I stated, for exam-
ple, that the basic mechanism of the emer-
gence of human immunodeficiency virus “is
still unproven,” that “there is some evidence”
for Salmonella drug resistance being acquired
from fish farms in Asia, that the widely
accepted belief that mad cow disease origi-
nated from scrapie in sheep is “still just a
hypothesis,” and that “perhaps” an infected
person first introduced West Nile virus into
the United States. However, Burke’s blanket
assertion in the review that “an infected arriv-
ing human could not have been the origin of
the West Nile epidemic in Queens, New
York” confuses fact with theory, indeed. This
may be his informed opinion, but it is far
from scientifically established fact.
The author receives royalties fom the publication
and distribution of this book.
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Hypothyroxinemia, Iodine
Deficiency, and Subtle 
Changes in Migration 
and Cytoarchitecture
In the Guest Editorial in the September
issue of EHP, Zoeller (2003) commented on
an article by Lavado-Autric et al. (2003).
Lavado-Autric et al. (2003) used the term
“hypothyroxinemia” in this article to indi-
cate that thyroxine (T4) or free T4 concen-
trations are low compared with values
usually found at the same stage of pregnancy
in normal women with adequate iodine
intake, with or without the presence of clini-
cal or subclinical hypothyroidism (when
thyroid-stimulating hormone is above nor-
mal values). This is important because, in
many instances, women in iodine-deficient
populations are hypothyroxinemic; these
women are not clinically hypothyroidal
because they have normal or above-normal
levels of circulating 3,5,3´-triiodothyronine
(T3) that can be supplied to the tissues.
It is important to note that the rats in
the study were treated drastically by Lavado-
Autric et al. (2003). The dams were first fed
a diet with a low iodine content (LID) for
10 days and given an incredibly high
amount of a goitrogen—1% perchlorate
(KClO4)—in the drinking water to lower
the initial content of iodine-containingcom-
pounds in the thyroid gland; the 1% KClO4
was then withdrawn. After dividing the rats
into three groups, Lavado-Autric et al.
(2003) treated one group with LID con-
taining potassium iodide (LID-plus-KI) to
ensure a normal iodine intake (approxi-
mately 10 µg iodine/day), the second group
with LID alone (LID-1), and the third
group with LID containing 0.005% KClO4
(LID-2). This third treatment was used to fur-
ther decrease thyroid uptake of the small
amounts of iodine contained in the LID itself
and in the supplements given to the rats
throughout pregnancy and lactation to pre-
ventnutritional deficiencies other than iodine.
In his editorial, Zoeller (2003) stated
the following:
Lavado-Autric et al. (2003) reported that subtle
TH [thyroid hormone] insufficiency in the preg-
nant rat disrupts the migration of neurons in the
fetal cortex and hippocampus.…
This was not subtle TH insufficiency. In
fact, Lavado-Autric et al. (2003) stated that 
T4 values in the LID-1 dams were well below
normal (< 10% of the values of LID-plus-KI
dams), and T3 values remained normal. In LID-2
dams, however, T3 values decreased, though
much less markedly than T4. Despitethe decrease
in T3 values, the reproductive performance of
these animals was normal, as was the postnatal
growth of the pups at [postnatal day 40].
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the subtle changes in cytoarchitectonic organiza-
tion found in the progeny of both LID-1 and
LID-2 dams indicate that the normal process of
brain maturation … [is] likely to be impaired.
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Hypothyroxinemia: Zoeller’s
Response
Soldin addresses an important issue that was
not fully developed in my editorial (Zoeller
2003a), specifically, the description of thy-
roid status in experimental animals designed
to model human conditions. There are two
separate issues in this regard. The first is that
the language describing thyroid status is well
defined for humans but not for experimen-
tal animals. Clinical assays for the various
hormones of the pituitary–thyroid axis are
standardized (and calibrated) across clinical
chemistry laboratories, and reference ranges
have been published for various subgroups
of the population (e.g., Adams et al. 1995;
Singh et al. 2003; Wiersinga 2001).
Therefore, terms such as “hypothyroxi-
nemia” and “subclinical (or mild) hypothy-
roidism” have very specific definitions for
humans. In contrast, experimental studies
are internally controlled (i.e., using control
groups), and there are no reference ranges
or assays that are calibrated across research
laboratories performing these assays.
Therefore, caution is needed when applying
terms such as “subclinical hypothyroidism”
to experimental animals. 
The second, and more important, issue is
that the vast majority of research focused on
identifying the role of thyroid hormone (TH)
in brain development has modeled severe
hypothyroidism (reviewed by Schwartz
1983). Perhaps for this reason, the “clinical”
symptoms of severe hypothyroidism in ani-
mals, including reduction in litter size, body
weight, and brain size, and a delay in
developmental landmarks such as tooth
eruption and eye opening, have come to be
viewed as cardinal developmental effects of
TH insufficiency. Therefore, by association,
if these “clinical” signs are not observed, the
implication is that there would be no other
effects on brain development. In large part,
the work by Lavado-Autric et al. (2003) was
testing whether “subtle” (my term) hypo-
thyroidism could affect brain development
(Zoeller 2003b).
By “subtle,” I meant that maternal thy-
roxine (T4) was reduced to a level below
that of control animals but that overt
effects on litter size, body weight, and
other characteristics were not observed.
Soldin is correct that the initial treatment
of young adult female rats described by
Lavado-Autric et al. (2003) was not subtle.
Subgroups of these animals were treated for
10 days with a low iodine diet plus 1%
potassium perchlorate in their drinking
water. However, the animals were then
taken off perchlorate treatment and placed
on specifically designed diets for 3 months
before being mated. Thus, the article by
Lavado-Autric et al. is not about perchlo-
rate treatment; it is about the sensitivity of
the developing brain to TH insufficiency
and the developmental timing of this vul-
nerability. The fact remains that there are
no experimental studies designed to deter-
mine what might be considered a no effect
level for maternal or neonatal TH insuffi-
ciency on brain development. However,
this will be an important issue to clarify as
we consider the significance of maternal
hypothyroxinemia or the effects of thyroid
toxicants on brain development. 
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Chemical Safety Requires Local
Government Action
In “REACHing for Chemical Safety,”
Brown (2003) described the European
Union’s proposed Registration, Evaluation,
and Authorisation of Chemicals (REACH)
legislation and the shocking ineffectiveness
of the laws currently governing toxic chem-
icals. Brown (2003) also revealed the
depressing extent to which U.S. environ-
mental officials, who are supposed to be
advocates for the public and the environ-
ment, have instead fallen in line with the
Bush administration’s pro-business poli-
cies. Much-needed reform of U.S. policy
on chemicals seems remote at best, but
glimmers of hope, and possibly the future,
exist outside the Washington, DC,
Beltway. Last summer, San Francisco,
California, became the first government
jurisdiction in the United States to adopt
the precautionary principle as a controlling
environmental policy. San Francisco has
also passed a resolution supporting a strong
REACH in Europe, which would clearly
benefit the people of California and else-
where in the United States by promoting a
safer global chemicals industry. Local com-
munities and states can and must take envi-
ronmental protection into their own hands;
Californians are showing how bridges to
Europe can help bypass the federal govern-
ment altogether. Official San Francisco
websites provide further information on
the San Francisco ordinance on the
Precautionary Principle Ordinance (SF
Environment 2003) and the REACH
Resolution (City and County of San
Francisco Board of Supervisors 2003). 
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The November 2003 Forum article “New Data on
Methylmercury and Fetuses” [Environ Health Perspect 111:A753
(2003)] incorrectly stated, in reference to methylmercury poison-
ing at Minamata Bay in the mid-1950s, “The hair mercury of
pregnant women in Minamata ranged from 25 to 50 ppm.” In
fact, there are no direct data on the hair mercury concentrations of
the pregnant Minamata women whose children had health prob-
lems associated with methylmercury poisoning. EHP regrets the
error. 
In Tables 3–7 of “Assessing Potential Risk of Heavy Metal
Exposure from Consumption of Home-Produced Vegetables by
Urban Populations” by Hough et al. [Environ Health Perspect
112:215–221 (2004)], the values “× 10” should be “× 100.” In
Table 3, the β1 values for lettuce should be –3.59 × 10–1 and the
β1 value for cabbage should be –6.23 × 10–2. 
A footnote was omitted from the body of Tables 2–4 in the article
“Urinary Levels of Seven Phthalate Metabolites in the U.S.
Population from the National Health and Nutrition Examination
Survey (NHANES) 1999–2000” by Silva et al. [Environ Health
Perspect 112:331–338 (2004)]. Footnote “a,” indicating the mean-
ing of italics in each of these tables, should have been placed in the
second line under “GM (geometric mean). EHP apologizes for the
error. Also, Silva et al. would like to clarify that the “No. (%)” values
in Tables 2–4 indicate sample size (percentage of detection). 
Orlando et al. discovered an error in their article, “Endocrine-
Disrupting Effects of Cattle Feedlot Effluent on an Aquatic
Sentinel Species, the Fathead Minnow” [Environ Health Perspect
112:353–358 (2004)]. In Table 3, a zero was omitted from the
value for gonadal mass under “Intermediate Site”; the correct
value is 0.088 ± 0.01 instead of 0.88 ± 0.01.
CORRECTIONS